Sapphiros

Sapphiros operates four disclosed subsidiaries: Satio, developing a consumer wearable diagnostic patch; GrapheneDx, building a handheld at-home testing device; a Cambridge-based molecular-detection unit focused on isothermal nucleic-acid amplification; and a Hove-based materials and manufacturing center producing printed electronics and lateral-flow tests. The firm controls its own UK manufacturing lines rather than outsourcing production.

Sapphiros does not publicly disclose its management team or investment committee on its website. Corporate filings show the US entity (Sapphiros LLC) and UK entity (Sapphiros UK Ltd) are registered but do not list directors or principals in publicly available materials. Decision-making structure is therefore unconfirmed from primary sources.

Sapphiros appears to be structured as a holding company or platform that acquires and operates diagnostics businesses rather than a traditional closed-end fund. It owns manufacturing assets and lists commercial and government clients — including Roche, BARDA, and the Gates Foundation — suggesting revenue may come from product sales and development contracts. No fund structures, limited partners, or reported AUM are disclosed.

KKR appears among a list of organizations on the Sapphiros website alongside commercial partners and government agencies, but the exact nature of the relationship is not disclosed. It could represent a strategic partnership, a client relationship, or an investment — Sapphiros provides no detail beyond the listing.

Manufacturing is concentrated at the Hove, UK facility, which is described as a center of excellence for extreme-volume lateral-flow production and printed electronics. The firm states the facility has a capacity of five billion units annually, making it one of the highest-volume diagnostics manufacturing sites publicly disclosed by a private platform.

The portfolio spans consumer-based patch diagnostics (Satio), molecular at-home testing (GrapheneDx), ultra-rapid isothermal amplification for infectious disease and genetic testing (Cambridge), and lateral-flow and printed-electronics formats (Hove). The common thread is low-cost, scalable platforms intended for both advanced and resource-limited settings.

Sapphiros is categorized as an asset manager with a private equity posture, but it operates more like an industrial platform than a fund manager. The ownership and capital source are not disclosed, so a family-office classification cannot be confirmed. Its structure — holding operating subsidiaries with physical manufacturing assets — is atypical for both traditional PE funds and family offices.